This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Donawho, C. K. Articles by Frost, D. J. Search for Related Content PubMed Articles by Donawho, C. K. Articles by Frost, D. J.

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Authors' Affiliations: ¹ Abbott Laboratories, Abbott Park, Illinois and ² Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland

Requests for reprints: David J. Frost, In Vivo Tumor Biology, Abbott Laboratories, R4N2 AP3, Abbott Park, IL 60064-6074. E-mail: david.frost{at}abbott.com.

Purpose: To evaluate the preclinical pharmacokinetics and antitumor efficacy of a novel orally bioavailable poly(ADP-ribose) polymerase (PARP) inhibitor, ABT-888.

Experimental Design: In vitro potency was determined in a PARP-1 and PARP-2 enzyme assay. In vivo efficacy was evaluated in syngeneic and xenograft models in combination with temozolomide, platinums, cyclophosphamide, and ionizing radiation.

Results: ABT-888 is a potent inhibitor of both PARP-1 and PARP-2 with K_is of 5.2 and 2.9 nmol/L, respectively. The compound has good oral bioavailability and crosses the blood-brain barrier. ABT-888 strongly potentiated temozolomide in the B16F10 s.c. murine melanoma model. PARP inhibition dramatically increased the efficacy of temozolomide at ABT-888 doses as low as 3.1 mg/kg/d and a maximal efficacy achieved at 25 mg/kg/d. In the 9L orthotopic rat glioma model, temozolomide alone exhibited minimal efficacy, whereas ABT-888, when combined with temozolomide, significantly slowed tumor progression. In the MX-1 breast xenograft model (BRCA1 deletion and BRCA2 mutation), ABT-888 potentiated cisplatin, carboplatin, and cyclophosphamide, causing regression of established tumors, whereas with comparable doses of cytotoxic agents alone, only modest tumor inhibition was exhibited. Finally, ABT-888 potentiated radiation (2 Gy/d x 10) in an HCT-116 colon carcinoma model. In each model, ABT-888 did not display single-agent activity.

Conclusions: ABT-888 is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models. This broad spectrum of chemopotentiation and radiopotentiation makes this compound an attractive candidate for clinical evaluation.

This article has been cited by other articles:

				A. H. Calvert and R. Plummer The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials Clin. Cancer Res., June 15, 2008; 14(12): 3664 - 3669. [Abstract] [Full Text] [PDF]

				B. Evers, R. Drost, E. Schut, M. de Bruin, E. van der Burg, P. W.B. Derksen, H. Holstege, X. Liu, E. van Drunen, H. B. Beverloo, et al. Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin Clin. Cancer Res., June 15, 2008; 14(12): 3916 - 3925. [Abstract] [Full Text] [PDF]

				R. Kinders, R. E. Parchment, J. Ji, S. Kummar, A. J. Murgo, M. Gutierrez, J. Collins, L. Rubinstein, O. Pickeral, S. M. Steinberg, et al. Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice Mol. Interv., December 1, 2007; 7(6): 325 - 334. [Abstract] [Full Text] [PDF]